Close Menu


News and reporting on cancer immunotherapy.

A recent paper details how, across several cancer types, high TMB is associated with improved outcomes with immunotherapy but worse outcomes without it.

Early data around an initial composite assay showed it can predict immunooncology drug responses more accurately than tumor mutational burden.

The grant, awarded by the Eurostars program, will support the European companies in their goal of advancing their mRNA-based kidney cancer vaccine.

The firm will collect stool and blood samples from 4,000 cancer patients and determine whether their microbiome composition affects their response to therapy.

The B44 supertype is associated with improved survival in melanoma patients treated with immunotherapy, but less so in NSCLC patients, due to mutational differences.

Researchers found that cancer patients with BRCA2 mutations respond particularly well to checkpoint inhibitors compared to those with BRCA1 mutations.

The company has begun Phase II trials of its bespoke treatment GRANITE and the off-the-shelf counterpart SLATE in combination with BMS's checkpoint inhibitors.  

The Phase I/II GOBLET trial will assess pelareorep plus Tecentriq in pancreatic, colorectal, and anal cancer patients and explore biomarkers of response.

Researchers showed that ctDNA levels predicted who would respond to first-line immune checkpoint inhibition but were not useful in second-line therapy.

Researchers are continuing to collect data on economic, racial, and other factors that could be addressed to make precision medicine access more equitable.